TERAZOSIN- terazosin hydrochloride capsule

Valsts: Amerikas Savienotās Valstis

Valoda: angļu

Klimata pārmaiņas: NLM (National Library of Medicine)

Nopērc to tagad

Produkta apraksts Produkta apraksts (SPC)
01-10-2022

Aktīvā sastāvdaļa:

Terazosin Hydrochloride (UNII: D32S14F082) (Terazosin - UNII:8L5014XET7)

Pieejams no:

Proficient Rx LP

SNN (starptautisko nepatentēto nosaukumu):

Terazosin Hydrochloride

Kompozīcija:

Terazosin 10 mg

Ievadīšanas:

ORAL

Receptes veids:

PRESCRIPTION DRUG

Ārstēšanas norādes:

Terazosin capsules are indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH). There is a rapid response, with approximately 70% of patients experiencing an increase in urinary flow and improvement in symptoms of BPH when treated with terazosin capsules. The long-term effects of terazosin capsules on the incidence of surgery, acute urinary obstruction or other complications of BPH are yet to be determined. Terazosin capsules are also indicated for the treatment of hypertension. Terazosin capsules can be used alone or in combination with other antihypertensive agents such as diuretics or beta-adrenergic blocking agents. Terazosin capsules are contraindicated in patients known to be hypersensitive to terazosin hydrochloride.

Produktu pārskats:

Terazosin Capsules are available in the following dosage strength: 10 mg Terazosin  Capsules, USP are available as light green opaque cap/body printed “TL 386” in black ink. Bottles of 30: NDC 63187-620-30 Bottles of 60: NDC 63187-620-60 Bottles of 90: NDC 63187-620-90 Dispense in a tight, light-resistant container as defined in the USP. Recommended storage: Store at 20° - 25°C (68° - 77°F) [see USP Controlled Room Temperature]. Protect from light and moisture. Rx only Revised 08/12 Jubilant Cadista Pharmaceuticals Inc. Salisbury, MD 21801, USA Repackaged by: Proficient Rx LP Thousand Oaks, CA 91320  For additional copies of the printed patient information/medication guide, please visit Error! Hyperlink reference not valid. or call 1-800-313-4623.

Autorizācija statuss:

Abbreviated New Drug Application

Produkta apraksts

                                TERAZOSIN- TERAZOSIN HYDROCHLORIDE CAPSULE
PROFICIENT RX LP
----------
TERAZOSIN CAPSULES, USP
DESCRIPTION
Terazosin hydrochloride, an alpha-1-selective adrenoceptor blocking
agent, is a
quinazoline derivative represented by the following chemical
name,molecular formula and
structural formula:
(RS)-Piperazine,
1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-
furanyl)carbonyl]-, monohydrochloride.C
H
ClN O
Terazosin hydrochloride is a white, crystalline substance, freely
soluble in water and
isotonic saline and has a molecular weight of 423.93. Each capsule,
for oral
administration, contains 1 mg, 2 mg, 5 mg or 10 mg of terazosin as
terazosin
hydrochlolde. In addition, each capsule contains the following
inactive ingredients:
colloidal silicon dioxide, lactose monohydrate, magnesium stearate,
and pregelatinized
starch. The gelatin capsule contains gelatin, silicon dioxide, sodium
lauryl sulfate, and
titanium dioxide. The 1 mg shell also contains black iron oxide; the 2
mg capsule shell
also contains D&C Yellow #10; the 5 mg capsule shell also contains D&C
Yellow #10,
FD&C Red #40 and D&C Red #28; the 10 mg capsule shell also contains
FD&C Green
#3 and D&C Yellow#10.
CLINICAL PHARMACOLOGY
PHARMACODYNAMICS
A. BENIGN PROSTATIC HYPERPLASIA (BPH)
The symptoms associated with BPH are related to bladder outlet
obstruction, which is
comprised of two underlying components: a static component and a
dynamic
component. The static component is a consequence of an increase in
prostate size.
Over time, the prostate will continue to enlarge. However, clinical
studies have
demonstrated that the size of the prostate does not correlate with the
severity of BPH
symptoms or the degree of urinary obstruction. The dynamic component
is a function
of an increase in smooth muscle tone in the prostate and bladder neck,
leading to
constriction of the bladder outlet. Smooth muscle tone is mediated by
sympathetic
19
26
5
4
nervous stimulation of alpha-1 adrenoceptors, which are abundant in
the prostate,
prostatic capsule and bladder 
                                
                                Izlasiet visu dokumentu
                                
                            

Meklēt brīdinājumus, kas saistīti ar šo produktu